A Phase 2, Open-Label, Dose-Titrating Safety and Efficacy Study of QGC001 Administered Orally, Twice Daily, Over 8 Weeks in Hypertensive Overweight Subjects of Multiple Ethnic and Racial Groups in the United States
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2017
At a glance
- Drugs QGC 001 (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms NEW-HOPE
- Sponsors Quantum Genomics
- 13 Nov 2017 Status changed from not yet recruiting to recruiting.
- 18 Sep 2017 Planned initiation date changed from 1 Sep 2017 to 1 Oct 2017.
- 28 Jun 2017 New trial record